Saturday 17 October 2026
Export WINT’s income statement to Excel — free account
Windtree Therapeutics, Inc.
WINT Healthcare Biotechnology
In the quarter to September 2025, EPS grew 99.5% and free cash flow grew 1.12%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow WINT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 4 | 5 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
698,506.32 | 475,684.11 | 1,696,184.62 | 228.59 | — | — | — | — | — |
Altman Z-Score |
21,759.50 | 12,534.28 | 35,474.06 | (7.03) | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(239.28) | (685.41) | (17.20) | (17.51) | — | — | — | — | — |
P/Operating CF |
(205,377.96) | (146,919.91) | (489,868.86) | (21.02) | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 44,525.03 | 1.53 | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Sales |
698,515.84 | 475,703.16 | 1,696,183.41 | 222.99 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
(42,465.37) | (33,567.08) | (192,178.94) | (4.54) | — | — | — | — | — |
EV/FCF |
(42,146.66) | (33,528.84) | (192,288.61) | (4.50) | — | — | — | — | — |
Quick Ratio |
0.42 | 0.15 | 1.22 | 2.89 | 2.76 | 4.54 | 2.51 | 1.08 | 0.31 |
Current Ratio |
0.54 | 0.19 | 1.24 | 3.05 | 2.96 | 4.77 | 3.00 | 1.35 | 0.45 |
Net Debt/EBITDA |
(0.54) | (0.61) | 0.14 | 0.11 | (0.03) | 0.22 | (0.43) | (0.63) | 0.03 |
Debt/Assets |
257.76% | 448.16% | 19.24% | 16.62% | 15.75% | 20.45% | 40.19% | 47.01% | 3.44% |
Debt/Equity |
(0.87) | (0.63) | 0.34 | 0.26 | 0.26 | 0.37 | 1.52 | 4.49 | 0.10 |
Asset Turnover |
0.08 | 0.23 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.85 | 0.85 | 0.45 | 0.90 | 0.78 | 0.35 | 0.50 | 0.66 | 2.81 |
Capex/Depreciation |
(0.13) | (0.02) | 0.01 | (0.53) | (1.73) | (0.01) | 0.01 | 0.00 | (0.07) |
Interest Coverage |
(15.11) | (12.10) | (11.49) | (50.29) | (242.54) | (677.89) | (779.87) | (411.94) | (111.23) |
| 384.07% | 94.09% | (157.29%) | (38.41%) | (45.08%) | (121.39%) | (151.11%) | (302.78%) | (81.98%) | |
| (146.05%) | (380.44%) | (56.63%) | (23.05%) | (28.09%) | (72.08%) | (69.55%) | (57.68%) | (18.20%) | |
ROIC |
0.00% | 0.00% | (15.35%) | (21.57%) | (26.92%) | (138.69%) | (135.31%) | (89.99%) | (178.02%) |
Return on Tangible Assets |
767.84% | 287.29% | (596.98%) | (163.13%) | (252.23%) | (345.45%) | (756.62%) | (1,295.72%) | 180.97% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
1,552.64% | 1,170.10% | 590.72% | 6,407.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
410.04% | 448.28% | 415.04% | 6,264.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.78 | 0.78 | 0.82 | 0.64 | 0.75 | 0.78 | 0.87 |
Share Based Compensation of Revenue |
82.52% | 111.45% | 53.41% | 3,394.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | (0.18) | — | — | — | — | — |
Graham Number |
56,917.09 | 53,264.97 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(60.59%) | (788.64%) | (64.76%) | (19.52%) | — | — | — | — | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | (21.66%) | — | — | — | — | — |
Revenue per Share |
4.91 | 1.44 | 0.40 | 990.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(80.74) | (20.47) | (3.51) | (123,315.00) | (84,383.33) | (39,440.00) | (27,788.57) | (3,124.88) | (292.81) |
Capex per Share |
(0.61) | (0.02) | 0.00 | (955.00) | (970.00) | (465.00) | 281.43 | (3.49) | (0.23) |
Free Cash Flow per Share |
(81.35) | (20.50) | (3.51) | (124,270.00) | (85,353.33) | (39,905.00) | (27,507.14) | (3,128.37) | (293.04) |
Cash per Share |
13.43 | 1.77 | 5.60 | 112,890.00 | 56,433.33 | 37,246.67 | 8,817.14 | 1,004.42 | 33.82 |
Shareholders Equity per Share |
(69.30) | (23.27) | 15.16 | 374,675.00 | 231,840.00 | 69,801.67 | 14,302.86 | 788.60 | 190.04 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.10 | 0.06 | 0.03 | 0.02 | 0.00 | 0.00 |
Book value per Share |
(69.30) | (23.27) | 15.16 | 374,675.00 | 231,840.00 | 69,801.67 | 14,302.86 | 788.60 | 190.04 |
Free Cash Flow |
(33.84) | (21.07) | (15.77) | (24.85) | (25.61) | (23.94) | (19.25) | (13.45) | (15.41) |
Working Capital |
(6.20) | (9.52) | 5.02 | 16.04 | 11.99 | 18.57 | 4.92 | 1.38 | (3.14) |
Capital Expenditures |
(0.25) | (0.02) | 0.01 | (0.19) | (0.29) | (0.28) | 0.20 | (0.01) | (0.01) |
Net Current Asset Value |
(31.33) | (25.03) | (25.63) | (20.18) | (25.21) | (9.42) | (20.56) | (23.64) | (15.30) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.12 | 0.02 | 0.00 | 0.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
1.86 | 1.25 | 1.28 | 0.45 | 0.18 | 44.72 | 76.25 | 17.16 | 1.63 |
Cash ROIC |
(1,925.09%) | 296.54% | (13.57%) | (21.19%) | (24.56%) | (30.11%) | (61.25%) | (58.63%) | (121.04%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Payables |
1.09 | 2.07 | 2.87 | 2.56 | 1.43 | 0.93 | 0.47 | 0.53 | 1.34 |
Average Assets |
27.04 | 6.52 | 61.37 | 119.19 | 115.93 | 93.84 | 56.37 | 35.18 | 30.14 |
Average Common Equity |
(10.28) | (26.37) | 22.10 | 71.52 | 72.24 | 55.72 | 25.95 | 6.70 | 6.69 |
Columns are period end dates